# Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

> **NCT02045017** · PHASE2 · COMPLETED · sponsor: **Celgene** · enrollment: 81 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide and Dexamethasone

## Key facts

- **NCT ID:** NCT02045017
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-28
- **Primary completion:** 2017-01-27
- **Final completion:** 2021-07-28
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02045017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02045017, "Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02045017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*